GamEvac-Combi
Heterologous VSV- and Ad5-vectored Ebola vaccine
From Wikipedia, the free encyclopedia
GamEvac-Combi (Russian: ГамЭвак-Комби) is a heterologous VSV- and Ad5-vectored Ebola vaccine. There is also a version called GamEvac which is a homologous Ad5-vectored vaccine.[1] GamEvac-Combi was developed by Gamaleya Research Institute of Epidemiology and Microbiology. As of 2015[update] the vaccine has been licensed in Russia for emergency use, on the basis of Phase 1 and Phase 2 clinical trials.[2]
| Vaccine description | |
|---|---|
| Target | Ebola |
| Vaccine type | Heterologous |
| Legal status | |
| Legal status |
|
Description
History
GamEvac-Combi was licensed by the Ministry of Health of the Russian Federation for emergency use in the territory of the Russian Federation in December 2015. The emergency license was based on Phase I and II clinical data of safety and immunogenicity.[2]